GlassScriptPhysician profile
Shervin Harandi
NPI 1063771509
$39,198.15
in general payments reported to CMS, 2019-2025
40 companies · $447 in 2025
The $447 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $4,176 · 2021: $7,673 · 2022: $2,337 · 2023: $875 · 2024: $449 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,771.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $33,451.03 | 2019-2024 | Senza |
| Abbvie INC. | $938.76 | 2021-2025 | |
| Medtronic USA, INC. | $647.54 | 2019-2020 | |
| Medtronic, INC. | $603.94 | 2021-2023 | Intellis Adaptivestim, Accurian |
| Pacira Therapeutics, INC. | $510.76 | 2019-2021 | |
| Tersera Therapeutics LLC | $315.08 | 2019-2023 | Prialt |
| Globus Medical, INC. | $208.90 | 2025 | Senza, Vyrsa V1 |
| Biodelivery Sciences International, INC. | $199.12 | 2019-2021 | |
| Allergan, INC. | $189.06 | 2019-2020 | |
| Boston Scientific Corporation | $178.72 | 2019-2023 | |
| Collegium Pharmaceutical, INC. | $178.29 | 2019-2023 | Belbuca |
| Scilex Pharmaceuticals INC. | $176.43 | 2019-2023 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.88 | 2019-2022 | |
| Abbott Laboratories | $136.01 | 2019-2023 | Proclaim |
| Horizon Therapeutics Plc | $121.63 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shervin Harandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.